Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ozanimod open-label extension for moderately to severely active Crohn's disease
NL-OMON56255Phase 3Active, not recruiting
- Sponsor
- Shanghai Celgen Biopharma
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of ozanimod in Crohn's disease (2 cohorts), sponsored by Shanghai Celgen Biopharma. Primary endpoints: Clinical remission by CDAI, Endoscopic improvement by SES-CD and 11 more. Started Mar 2020; status: active, not recruiting.
02
Drugs
ozanimod
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on NL-OMON56255.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON56255.